Co-occurring depressive symptoms in the older patient with schizophrenia

Drugs and Aging

Volumn 25, Issue 8, 2008, Pages 631-647

  Kasckow, John W ^a,b   Zisook, Sidney ^c  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

Author keywords

Antidepressants, therapeutic use; Antipsychotics, therapeutic use; Citalopram, therapeutic use; Depression, treatment; Elderly; Electroconvulsive therapy; Fluoxetine, therapeutic use; Fluvoxamine, therapeutic use; Schizophrenia, treatment

Indexed keywords

ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CHLORPROMAZINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CITALOPRAM; CLOZAPINE; FLUOXETINE; FLUVOXAMINE; HALOPERIDOL; NEUROLEPTIC AGENT; NORTRIPTYLINE; OLANZAPINE; PERPHENAZINE; PLACEBO; QUETIAPINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; THIORIDAZINE; ZIPRASIDONE;

ADULT; AGED; AGITATION; AGRANULOCYTOSIS; AKATHISIA; ANXIETY DISORDER; BIPOLAR DISORDER; BRADYKINESIA; CLINICAL TRIAL; COMORBIDITY; CONFUSION; CONTROLLED STUDY; DEMENTIA; DEPRESSION; DIABETES MELLITUS; DRUG DOSE REGIMEN; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; DRUG SUBSTITUTION; ELECTROCONVULSIVE THERAPY; EXTRAPYRAMIDAL SYNDROME; FOLLOW UP; HUMAN; LOW DRUG DOSE; MAJOR DEPRESSION; MOOD DISORDER; ORTHOSTATIC HYPOTENSION; PARKINSONISM; PRIORITY JOURNAL; PSYCHOSIS; PSYCHOTHERAPY; QUALITY OF LIFE; REMISSION; REVIEW; RIGIDITY; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SEIZURE; SIDE EFFECT; TARDIVE DYSKINESIA; THOUGHT DISORDER; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT PLANNING; TREMOR;

AGE FACTORS; AGED; ANTIDEPRESSIVE AGENTS; CLINICAL TRIALS AS TOPIC; DEPRESSIVE DISORDER, MAJOR; HUMANS; PSYCHOTIC DISORDERS; SCHIZOPHRENIA;

EID: 48249090086     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-200825080-00002     Document Type: Review

References (115)

1. Siris SG, Addington D, Azorin J, et al. Depression in schizophrenia: recognition and management in the USA. Schizophr Res 2001; 47: 185-97
2. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, DSM-III. 3rd ed. Washington, DC: American Psychiatric Association, 1980
3. Kessler RC, McGonagle KA, Zhao S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Arch Gen Psychiatry 1994; 51: 8-19
4. Siris SG. Depression in the course of schizophrenia. In: Hwang MY, Bermanzohn PC, editors. Schizophrenia and comorbid conditions. Washington, DC: American Psychiatric Press, Inc., 2001: 31-56
5. Cohen CI. Studies of the course and outcome of schizophrenia in later life. Psychiatr Serv 1995; 46: 877-879, 889
6. Jin H, Zisook S, Palmer BW, et al. Association of depressive symptoms and functioning in schizophrenia: a study in older outpatients. J Clin Psychiatry 2001; 62: 797-803
7. Zisook S, McAdams LA, Kuck J, et al. Depressive symptoms in schizophrenia. Am J Psychiatry 1999; 156: 1736-43
8. Schwartz RC, Cohen BN. Psychosocial correlates of suicidal intent among patients with schizophrenia. Compr Psychiatry 2001; 42: 118-23
9. Joukamaa M, Heliovaara M, Knekt P, et al. Mental disorders and cause-specific mortality. Br J Psychiatry 2001; 179: 498-502
10. First MB. Mutually exclusive versus co-occurring diagnostic categories: the challenge of diagnostic comorbidity. Psychopathology 2005; 38 (4): 206-10
11. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, DSM-IV. 4th ed. Washington, DC: American Psychiatric Association, 1994
12. World Health Organization. International statistical classification of diseases and related health problems. 10th rev. Geneva: World Health Organization, 2007
13. Bressan RA, Chaves AC, Pilowsky LS, et al. Depressive episodes in stable schizophrenia: critical evaluation of the DSM-IV and ICD-10 diagnostic criteria. Psychiatry Res 2003; 117: 47-56
14. Knights A, Hirsch SR. "Revealed" depression and drug treatment for schizophrenia. Arch Gen Psychiatry 1981; 38: 806-11
15. Birchwood M, Iqbal Z, Chadwick P, et al. Cognitive approach to depression and suicidal thinking in psychosis. 1: ontogeny of post-psychotic depression. Br J Psychiatry 2000; 177: 516-21
16. Bressan RA, Costa DC, Jones HM, et al. Typical antipsychotic drugs -D(2) receptor occupancy and depressive symptoms in schizophrenia. Schizophr Res 2002; 56: 31-6
17. Van Putten T, May RP. "Akinetic depression" in schizophrenia. Arch Gen Psychiatry 1978; 35: 1101-7
18. Leo RJ. Movement disorders associated with serotonin selective reuptake inhibitors. J Clin Psychiatry 1996; 57: 449-54
19. American Psychiatric Association. Diagnostic and statistical manual of mental disorders - text revision, DSM-IV-TR. 4th ed. Washington, DC: American Psychiatric Association, 2000: 320
20. McGlashan TH, Carpenter WT. An investigation of the postpsychotic depressive syndrome. Am J Psychiatry 1976; 133: 14-9
21. Birchwood M, Iqbal Z, Uptjegrove R. Psychologic pathways to depression in schizophrenia. Eur Arch Psychiatry Clin Neurosci 2005; 225: 202-12
22. Chan Y, Parisier SE, Neufeld G. Atypical antipsychotics in older adults. Pharmacotherapy 1999; 19: 811-82
23. Tariot PN. The older patient: the ongoing challenge of efficacy and tolerability. J Clin Psychiatry 1999; 60 Suppl. 23: 29-33
24. Kasckow JW, Mulchahey JJ, Aslam M, et al. When and how to use SSRIs to treat late-life depression. Curr Psychiatry 2003; 2: 43-7
25. Kasckow JW, Mohamed S, Granholm E, et al. Use of novel antipsychotics in older patients with schizophrenia. In: Cohen C, editor. Schizophrenia into later life treatment, research and policy. Washington, DC: APA Press, 2003: 195-204
26. Calgiuri MP, Lacro JP, Jeste DV. Incidence and predictors of drug induced parkinsonism in older psychiatric patients treated with very low doses of neuroleptics. J Clin Psychopharmacol 1999; 19: 322-8
27. Jeste DV, Lacro JP, Palmer B, et al. Incidence of tardive dyskinesia in early stages of low-dose treatment with typical neuroleptics in older patients. Am J Psychiatry 1999; 156: 309-11
28. Jeste DV, Lacro JP, Bailey A, et al. Lower incidence of tardive dyskinesia with risperidone compared with haloperidol in older patients. J Am Geriatric Soc 1999; 47: 716-9
29. Derry S, Moore RA. Atypical antipsychotics in bipolar disorder: systematic review of randomised trials. BMC Psychiatry 2007; 7: 40
30. Dando TM, Keating GM. Quetiapine: a review of its use in acute mania and depression associated with bipolar disorder. Drugs 2005; 65: 2533-51
31. Alexopoulos GS, Streim J, Carpenter D, et al. Expert Consensus Panel for Using Antipsychotic Drugs in Older Patients: using antipsychotic agents in older patients. J Clin Psychiatry 2004; 65 Suppl. 2: 5-99
32. Ritchie CW, Chiu E, Harrigan S, et al. The impact upon extrapyramidal side effects, clinical symptoms and quality of life of a switch from conventional to atypical antipsychotics (risperidone or olanzapine) in elderly patients with schizophrenia. Int J Geriatr Psychiatry 2003; 18: 432-40
33. Barak Y, Shamir E, Weizman R. Would a switch from typical antipsychotics to risperidone be beneficial for elderly schizophrenic patients? A naturalistic, long-term, retrospective, comparative study. J Clin Psychopharmacol 2002; 22: 115-20
34. Hwang JP, Yang CH, Yu HC, et al. The efficacy and safety of risperidone for the treatment of geriatric psychosis. J Clin Psychopharmacol 2001; 21: 583-7
35. Verma S, Orengo CA, Kunik ME, et al. Tolerability and effectiveness of atypical antipsychotics in male geriatric inpatients. Int J Geriatr Psychiatry 2001; 16: 223-7
36. Davidson M, Harvey PD, Vervarcke J, et al. A long-term, multicenter, open-label study of risperidone in elderly patients with psychosis. On behalf of the Risperidone Working Group. Int J Geriatr Psychiatr 2000; 15: 506-14
37. Madhusoodanan S, Brecher M, Brenner R, et al. Risperidone in the treatment of elderly patients with psychotic disorders [published erratum appears in Am J Geriatr Psychiatry 1999; 7: 268]. Am J Geriatr Psychiatry 1999; 7: 132-8
38. Madhusoodanan S, Brenner R, Alcantra A. Clinical experience with quetiapine in elderly patients with psychotic disorders. J Geriatr Psychiatry Neurol 2000; 13: 28-32
39. Tariot PN, Salzman C, Yeung PP, et al. Long-term use of quetiapine in elderly patients with psychotic disorders. Clin Ther 2000; 22: 1068-84
40. McManus DQ, Arvanitis LA, Kowalcyk BB. Quetiapine, a novel antipsychotic: experience in elderly patients with psychotic disorders: Seroquel Trial 48 Study Group. J Clin Psychiatry 1999; 60: 292-8
41. Hwang JP, Yang CH, Lee TW, et al. The efficacy and safety of olanzapine for the treatment of geriatric psychosis. J Clin Psychopharmacol 2003; 23: 113-8
42. Barak Y, Shamir E, Zemishlani H, et al. Olanzapine vs. haloperidol in the treatment of elderly chronic schizophrenia patients. Prog Neuropsychopharmacol Biol Psychiatry 2002; 26: 1199-202
43. Madhusoodanan S, Brenner R, Suresh P, et al. Efficacy and tolerability of olanzapine in elderly patients with psychotic disorders: a prospective study. Ann Clin Psychiatry 2000; 12: 11-8
44. American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocrinologists; North American Association for the Study of Obesity. Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes. Diabetes 2004; 27: 596-601
45. Glassman AH, Bigger JT. Antipsychotic drugs: prolonged QTc interval, torsade de pointe, and sudden death. Am J Psychiatry 2001; 158: 1774-82
46. Vartiainen H, Tihonen J, Putkonen A, et al. Citalopram, a selective serotonin reuptake inhibitor, in the treatment of aggression in schizophrenia. Acta Psychiatr Scand 1995; 91: 348-51
47. Silver H, Nassar A. Fluvoxamine improves negative symptoms in treated chronic schizophrenia: an add-on double-blind, placebo-controlled study. Biol Psychiatry 1992; 31: 698-704
48. Addington D, Addington J, Patten S. Double-blind, placebo-controlled comparison of the efficacy of sertraline as treatment for a major depressive episode in patients with remitted schizophrenia. J Clin Psychopharmacol 2002; 22: 20-5
49. Buchanan RW, Kirkpatrick B, Bryant N, et al. Fluoxetine augmentation of clozapine treatment in patients with schizophrenia. Am J Psychiatry 1996; 153: 1625-7
50. Goff DC, Midha KK, Sarid-Segal O, et al. A placebo-controlled trial of fluoxetine added to neuroleptic in patients with schizophrenia. Psychopharmacology 1995; 117: 417-23
51. Spina E, DeDomenico P, Ruello C, et al. Adjunctive fluoxetine in the treatment of negative symptoms in chronic schizophrenia patients. Int Clin Psychopharmacol 1994; 9: 281-28
52. Salokangas RK, Saarijarvi S, Taiminen T, et al. Citalopram as an adjuvant in chronic schizophrenia: a double-blind placebo-controlled study. Acta Psychiatr Scand 1996; 94: 175-80
53. Kasckow JW, Mohamed S, Thallasinos AS, et al. Antidepressant augmentation of antipsychotic treatment in older schizophrenia patients. Int J Geriatr Psychiatry 2001; 16: 1163-7
54. Pugh R. Rehabilitation and long-term management. In: Copeland JRM, Abou-Saleh MT, Blazer DG, editors. Principles and practice of geriatric psychiatry. 2nd ed. Chichester: John Wiley and Sons, Ltd, 2002: 517-22
55. Karim S, Overshott R, Burns A. Older people with schizophrenia. Aging Ment Health 2005; 9: 315-24
56. Liberman RP, Eckman TA. Dissemination of skills training modules to psychiatric facilities: overcoming obstacles to the utilization of a rehabilitation innovation. Br J Psychiatry Suppl; 1989 Jul; (5): 17-22
57. Liberman RP, Wallace CJ, Blackwell G, et al. Innovations in skills training for the seriously mentally ill: the UCLA Social and Independent Living Skills Modules. Innovations Res 1993; 2: 43-60
58. Heinssen RK, Liberman RP, Kopelowicz A. Psychosocial skills training for schizophrenia: lessons from the laboratory. Schizophr Bull 2000; 26: 21-46
59. Granholm E, McQuaid JR, McClure FS, et al. A randomized, controlled trial of cognitive behavioral social skills training for middle-aged and older outpatients with chronic schizophrenia. Am J Psychiatry 2005; 162: 520-9
60. Audini B, Marks IM, Lawrence RE, et al. Home based versus out-patient/inpatient care for people with serious mental illness: phase II of a controlled study. Br J Psychiatry 1994; 165: 204-10
61. Borland A, McRae J, Lycan C. Outcomes of five years of continuous intensive care management. Hosp Community Psychiatry 1989; 40: 369-76
62. Lafave HG, de Souza HR, Gerber GJ. Assertive community treatment of severe mental illness: a Canadian experience. Psychiatr Serv 1996; 47: 757-9
63. Muijen M, Cooney M, Strathdee G, et al. Community psychiatric nurse teams: intensive support versus geriatric care. Br J Psychiatry 1994; 165: 211-7
64. Stein LI, Test MA. Alternative to mental hospital treatment. I: conceptual model, treatment program, and clinical evaluation. Arch Gen Psychiatry 1980; 37: 392-7
65. Wood K, Anderson J. The effect on hospital admissions of psychiatric case management involving general practitioners: preliminary results. Aust N Z J Psychiatry 1995; 29: 223-9
66. Mohamed S, Kasckow JW, Granholm E, et al. Community based treatment of schizophrenia and other severe mental illness. In: Cohen C, editor. Schizophrenia into later life: treatment, research and policy. Washington, DC: APA Press, 2003: 205-22
67. Ford R, Beadsmore A, Ryan P, et al. Providing the safety net: case management for people with serious mental illness. J Ment Health 1995; 1: 91-7
68. Macias C, Kinney R, Farley OW, et al. The role of case management within a community support system: partnership with psychosocial rehabilitation. Community Ment Health J 1994; 30: 323-39
69. Hornstra RK, Bruce-Wolfe V, Sagduyu K, et al. The effect of intensive case management on hospitalization of patients with schizophrenia. Hosp Community Psychiatry 1993; 44: 844-7
70. Rossler W, Loffler W, Fatkenheuer B, et al. Does case management reduce the rehospitalization rate? Acta Psychiatrica Scand 1992; 86: 445-9
71. Rossler W, Loffler W, Fatkenheuer B, et al. Case management for schizophrenic patients at risk for rehospitalization: a case control study. Eur Arch Psychiatry Clin Neurosci 1995; 246: 29-36
72. Quinlaven R, Hough R, Crowell A, et al. Service utilization and costs of care for severely mentally ill clients in an intensive case management program. Psychiatr Serv 1995; 46: 365-71
73. Franklin JL, Solovitz B, Mason M, et al. An evaluation of case management. Am J Public Health 1987; 77: 674-8
74. Nierenberg AA, Katz J, Fava M. A critical overview of the pharmacologic management of treatment-resistant depression. Psychiatr Clin North Am 2007; 13-29
75. Kendler KS, McGuire M, Gruenberg AM, et al. Examining the validity of DSM-III-R schizoaffective disorder and its putative subtypes in the Roscommon family study. Am J Psychiatry 1995; 152: 755-64
76. Danileviciute V. Schizoaffective disorder: clinical symptoms and present-day approach to treatment [in Lithuanian]. Medicina (Kaunas) 2002; 38: 1057-65
77. Azorin JM, Kaladjian A, Fakra E. Current issues on schizoaffective disorder. Encephale 2005; 31: 359-65
78. Levinson DF, Umapathy C, Musthaq M. Treatment of schizoaffective disorder and schizophrenia with mood symptoms. Am J Psychiatry 1999; 156: 1138-48
79. Bartels SJ, Drake RE. Depressive symptoms in schizophrenia: comprehensive differential diagnosis. Compr Psychiatry 1988; 29: 467-83
80. Leff J. Depressive symptoms in the course of schizophrenia. In: DeLisi LE, editor. Depression in schizophrenia. Washington, DC: American Psychiatric Press, 1990: 3-23
81. Stern MJ, Pillsbury JA, Sonnenberg SM. Postpsychotic depression in schizophrenia. Compr Psychiatry 1972; 13: 591-8
82. Tollefson G, Sanger TM, Lu Y, et al. Depressive signs and symptoms in schizophrenia. Arch Gen Psychiatry 1998; 55: 250-8
83. Kay SR, Sevy S. Pyramidal model of schizophrenia. Schizophr Bull 1990; 16: 537-45
84. Jin H, Zisook S, Patterson TL, et al. Depressive symptoms, functioning, and well-being in older outpatients with schizophrenia. J Clin Psychiatry 2001; 62: 797-803
85. Birchwood M, Mason R, MacMillan F, et al. Depression, demoralization and control over psychotic illness: a comparison of depressed and non-depressed patients with a chronic psychosis. Psychol Med 1993; 23: 387-95
86. Tollefson GD, Andersen SW, Tran PV. The course of depressive symptoms in predicting relapse in schizophrenia: a double-blind, randomized comparison of olanzapine and risperidone. Biol Psychiatry 1999; 46: 365-73
87. Zisook S, Nyer M, Kasckow JW, et al. Depressive symtom pattern in patients with chronic schizophrenia and subsyndromal depression. Schizophr Res 2006; 86: 226-33.
88. Zisook S, Montross L, Kasckow J, et al. Subsyndromal depressive symptoms in middle-aged and older persons with schizophrenia. Am J Geriatr Psychiatry 2007; 15 (12): 1005-14
89. Cohen CI, Talavera N, Hartung R. Predictors of subjective well being among older, community-dwelling persons with schizophrenia. Am J Geriatr Psychiatry 1999; 5: 145-55
90. Diwan S, Cohen CI, Bankole AO, et al. Depression in older adults with schizophrenia spectrum disorders: prevalence and associated factors. Am J Geriatr Psychiatry 2007; 15 (12): 991-8
91. Graham C, Arthus A, Howard R. The social functioning of older adults with schizophrenia. Aging Ment Health 2002; 6: 149-53
92. Gupta S, Steinmeyer CH, Lockwood K, et al. Comparison of older patients with bipolar disorder and schizophrenia/schizoaffective disorder. Am J Geriatr Psychiatry 2007; 15: 627-33
93. Kasckow J, Montross L, Golshan S, et al. Suicidality in middle aged and older patients with schizophrenia and depressive symptoms: relationship to functioning and quality of life. Int J Geriatr Psychiatry 2007; 22: 1223-8
94. Taiminen T, Syvalahti E, Saarijarvi S, et al. Citalopram as an adjuvant in schizophrenia: further evidence for a serotonergic dimension in schizophrenia. Int Clin Psychopharmacol 1997; 12: 31-5
95. Flores BH, Schatzberg AF. Psychotic depression In: Stein DJ, Kupfer D, Schatzberg AF, editors. Textbook of mood disorders. Washington, DC: American Psychiatric Publishing Inc., 2006: 561-71
96. Ohayon MM, Schatzberg AF. Prevalence of depressive episodes with psychotic features in the general population. Am J Psychiatry 2002; 159: 1855-61
97. Coryell W, Pfohl B, Zimmerman M. The clinical and neuroendocrine features of psychotic depression. J Nerv Ment Dis 1984; 172: 521-8
98. Meyers BS, Greenberg R. Late-life delusional depression. J Affect Disord 1986; 11: 133-7
99. Kivela SL, Pahkala K, Laippala P. Prevalence of depression in an elderly population in Finland. Acta Psychiatr Scand 1988; 78: 401-13
100. Ostling S, Skoog I. Psychotic symptoms and paranoid ideation in a nondemented population-based sample of the very old. Arch Gen Psychiatry 2002; 59: 53-9
101. Schwartz JE, Fennig S, Tanenberg-Karant M, et al. Congruence of diagnoses 2 years after a first-admission diagnosis of psychosis. Arch Gen Psychiatry 2000; 57: 593-600
102. Nelson JC, Charney DS. The symptoms of major depressive illness. Am J Psychiatry 1981; 138: 1-13
103. Burch Jr EA, Anton RF, Carson WH. Mood congruent and incongruent psychotic depressions: are they the same? J Affect Disord 1994; 31: 275-80
104. Leyton M, Corin E, Martial J, et al. Psychotic symptoms and vulnerability to recurrent major depression. J Affect Disord 1995; 33: 107-15
105. Alexopoulos GS. Affective disorders. In: Sadavoy J, Lazarus LW, Jarvik LF, et al., editors. Comprehensive textbook of geriatric psychiatry. 2nd ed. Washington, DC: APA Press, 1996: 563-92
106. Pini S, Cassano GB, Dell'Osso L, et al. Insight into illness in schizophrenia, schizoaffective disorder, and mood disorders with psychotic features. Am J Psychiatry 2001; 158: 122-5.
107. Jeste DV, Heaton SC, Paulsen JS, et al. Clinical and neuropsychological comparison of psychotic depression with nonpsychotic depression and schizophrenia. Am J Psychiatry 1996; 153: 490-6
108. Hill SK, Keshavan MS, Thase ME, et al. Neuropsychological dysfunction in antipsychotic-naive first-episode unipolar psychotic depression. Am J Psychiatry 2004; 161: 996-1003
109. Mulsant BH, Haskett RF, Prudic J, et al. Low use of neuroleptic drugs in the treatment of psychotic major depression. Am J Psychiatry 1997; 154: 559-61
110. Wijkstra J, Lijmer J, Balk F, et al. Pharmacological treatment for psychotic depression. Cochrane Database Syst Rev 2005 Oct 19; (4): CD004044
111. Meyers BS, Klimstra SA, Gabriele M, et al. Continuation treatment of delusional depression in older adults. Am J Geriatr Psychiatry 2001; 9: 415-22
112. Flint AJ, Rifat SL. The treatment of psychotic depression in later life: a comparison of pharmacotherapy and ECT. Int J Geriatr Psychiatry 1998; 13: 23-8
113. Birkenhager TK, Pluijms EM, Lucius SA. ECT response in delusional versus non-delusional depressed inpatients. J Affect Disord 2003; 74: 191-5
114. Spiker DG, Stein J, Rich CL. Delusional depression and electroconvulsive therapy: one year later. Convuls Ther 1985; 1: 167-72
115. O'Connor MK, Knapp R, Husain M, et al. The influence of age on the response of major depression to electroconvulsive therapy: a C.O.R.E. report. Am J Geriatr Psychiatry 2001; 9: 382-90